Epidemiology and prevention of Human Papillomavirus

被引:87
作者
Manini, I [1 ]
Montomoli, E. [1 ,2 ]
机构
[1] Univ Siena, Dept Mol & Dev Med, Via Aldo Moro 2, I-53100 Siena, Italy
[2] VisMederi Srl, Siena, Italy
来源
ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITA | 2018年 / 30卷 / 04期
关键词
Cervical cancer; Prevention; 9-valent HPV vaccine;
D O I
10.7416/ai.2018.2231
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Human papillomavirus is the most common sexually transmitted infection, and skin-to-skin genital contact is sufficient for virus transmission. Cervical cancer is the second-most common cancer in women living in less developed regions, with an estimated 445,000 new cases in 2012 and 230,000 deaths every year. Until now, more than 200 types of HPV have been identified, and about 15 types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68, -82) have been shown to cause cervical cancer because they are able to transform infected cells into malignant tumor cells. The bivalent vaccine containing the serotypes 16 and 18 and the quadrivalent vaccine containing the serotypes 16, 18, 6 and 11, have been used in Italy for many years. The European Medicines Agency authorized marketing of the Gardasil 9 vaccine in the European Union on June 2015. Today, Public Health targets the immunization of adolescents of both genders based on new and important scientific evidence for maximum protection from all HPV related pathologies directly preventable with vaccination.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 16 条
[1]  
Azzari C, 2016, RIAP RIV IMMUNOLOGIA, V3, P38
[2]   The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma [J].
Brandao Berti, Fernanda Costa ;
Lombardi Pereira, Ana Paula ;
Martelossi Cebinelli, Guilherme Cesar ;
Trugilo, Kleber Paiva ;
de Oliveira, Karen Brajao .
CYTOKINE & GROWTH FACTOR REVIEWS, 2017, 34 :1-13
[3]   Worldwide burden of cancer attributable to HPV by site, country and HPV type [J].
de Martel, Catherine ;
Plummer, Martyn ;
Vignat, Jerome ;
Franceschi, Silvia .
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (04) :664-670
[4]  
de Sanjose S, 2012, Vaccine, V30 Suppl 4, pD1, DOI 10.1016/S0264-410X(12)01435-1
[5]  
European Medicines Agency, GARD HUM PAP VACC TY
[6]  
European Medicines Agency, GARD
[7]  
European Medicines Agency, CERV HUM PAP VACC TY
[8]   Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions [J].
Giuliano, Anna R. ;
Tortolero-Luna, Guillermo ;
Ferrer, Elena ;
Burchell, Ann N. ;
de Sanjose, Silvia ;
Kjaer, Susanne Kruger ;
Munoz, Nubia ;
Schiffman, Mark ;
Bosch, F. Xavier .
VACCINE, 2008, 26 :K17-K28
[9]   Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines [J].
Hartwig, Susanne ;
Baldauf, Jean-Jacques ;
Dominiak-Felden, Geraldine ;
Simondon, Francois ;
Alemany, Laia ;
de Sanjose, Silvia ;
Castellsague, Xavier .
PAPILLOMAVIRUS RESEARCH, 2015, 1 :90-100
[10]   An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11-15 Years of Age [J].
Kosalaraksa, Pope ;
Mehlsen, Jesper ;
Vesikari, Timo ;
Forsten, Aino ;
Helm, Klaus ;
Van Damme, Pierre ;
Joura, Elmar A. ;
Ciprero, Karen ;
Maansson, Roger ;
Luxembourg, Alain ;
Sobanjo-ter Meulen, Ajoke .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (06) :627-634